Federal Contractor Profile
Lovelace Biomedical Research Institute
$137M obligated·169 awards·6 agencies·14 NAICS
Federal Contracts
Showing award actions 1–50 of 209 funded award actions, most recent first.
- Contracts with positive obligations
- 169
- Funded award actions shown
- 209
- Obligations shown
- $137M
- Awarding agencies
- 6
This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.
Award data as of November 5, 2026. Source: USAspending federal award records.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Sep 25, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH OLAO | 75N98026F00001 | 541714 | GLP REPEAT DOSE TOXICOLOGY STUDY FOR A LIVE-ATTENUATED RESPIRATORY VIRUS VACCINE. | $340K |
| Sep 14, 2026 | Department of Health and Human ServicesFDA OFFICE OF ACQ GRANT SVCS | 75F40126F19003 | 541690 | NICOTINE FLUX: INVESTIGATING THE IMPACT OF ENDS OUTPUT POWER AND HEATING ELEMENT ON ABUSE LIABILITY | $3.0M |
| Aug 21, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50126F61002 | 541714 | RTOR BIO-AMT-2312: ASSESSMENT OF THE THERAPEUTIC POTENTIAL OF CHLOROQUINE AND OSELTAMIVIR IN TWO (2) LETHAL MODELS OF INFLUENZA A H5N1 | $3.7M |
| Aug 5, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95021F00001 | 541715 | CHARACTERIZATION OF A NON-PARALYZING BONT-BASED BIOPHARMACEUTICAL FOR THE TREATMENT OF NEUROPATHIC PAIN | $351K |
| Jul 17, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123F61001 | 541714 | BIO-AMT-2301: IDIQ CONTRACT MANAGEMENT SUPPORT ACTIVITIES | $22K |
| Jun 23, 2026 | Department of DefenseDEFENSE HEALTH AGENCY | W81XWH22P0157 | 511210 | LICENSE AND MAINTENANCE SUPPORT, ON-SITE SUPPORT SERVICES FOR VSP WRAIR. | $44K |
| Jun 22, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95023F00002 | 541715 | EFFICACY AND SAFETY EVALUATION OF LEAD GENE THERAPY CANDIDATE IN NEUROMUSCULAR JUNCTION (NMJ) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT | $303K |
| May 29, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00001 | 541712 | NON-CLINICAL SAFETY ASSESSMENT OF GENE THERAPY (PCCA, MMAB, DOK7 AND COLQ) TO SUPPORT PLATFORM GENE THERAPY FOR CONGENITAL MYASTHENIC DISEASES (DOK7, COLQ) AND ACIDEMIA (PCCA, MMAB) | $1.3M |
| May 29, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95021F00002 | 541715 | EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN METHYL MELANOMIC ACIDEMIA (MMAB) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT. | $86K |
| May 7, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123F61001 | 541714 | RADNUC 2201: PERFORMANCE VERIFICATION OF INSTITUTIONAL RADIATION DOSE RESPONSE FOR ACUTE RADIATION SYNDROME (ARS) ANIMAL MODELS (RODENT, RABBIT, MINIPIG, OR NON-HUMAN PRIMATE [NHP]) | $148K |
| Apr 1, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93022F00001 | 541715 | THE CONTRACTOR SHALL PERFORM THE TRANSFER, VALIDATION AND QUALIFICATION OF BIOANALYTICAL METHODS FOR DETECTION OF CABOTEGRAVIR AND LEVONORGESTREL IN RAT AND NONHUMAN PRIMATE PLASMA | $55K |
| Sep 30, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93025D00021 | 541715 | EVALUATION AND TESTING SERVICES (ETS) FOR VACCINES AND OTHER BIOLOGICS FOR INFECTIOUS DISEASES. | $10K |
| Sep 22, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123F61001 | 541714 | RADNUC 2201: PERFORMANCE VERIFICATION OF INSTITUTIONAL RADIATION DOSE RESPONSE FOR ACUTE RADIATION SYNDROME (ARS) ANIMAL MODELS (RODENT, RABBIT, MINIPIG, OR NON-HUMAN PRIMATE [NHP]) | $2.0M |
| Sep 19, 2025 | Department of Health and Human ServicesFDA OFFICE OF ACQ GRANT SVCS | 75F40125P00216 | 541380 | SOLE SOURCE AWARD OF A 24-MONTH PERIOD, FIRM FIXED PRICE (FFP), ENDS TOXICOLOGICAL STUDIES FOR CENTER FOR TOBACCO PRODUCTS (CTP). | $7.1M |
| Aug 27, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93022F00001 | 541715 | THE CONTRACTOR SHALL PERFORM THE TRANSFER, VALIDATION AND QUALIFICATION OF BIOANALYTICAL METHODS FOR DETECTION OF CABOTEGRAVIR AND LEVONORGESTREL IN RAT AND NONHUMAN PRIMATE PLASMA | $139K |
| Jul 17, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123F61001 | 541714 | BIO-AMT-2301: IDIQ CONTRACT MANAGEMENT SUPPORT ACTIVITIES | $21K |
| Jul 9, 2025 | Department of DefenseARMY MED RES ACQ ACTIVITY | W81XWH22P0157 | 511210 | LICENSE AND MAINTENANCE SUPPORT, ON-SITE SUPPORT SERVICES FOR VSP WRAIR. | $42K |
| Jun 30, 2025 | Department of Health and Human ServicesFDA OFFICE OF ACQ GRANT SVCS | 75F40119C10161 | 541380 | STUDY OF E-CIGARETTE AEROSOL TOXICITY IN IN VIVO NONCLINICAL MODELS. | $9.8M |
| May 19, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00001 | 541712 | NON-CLINICAL SAFETY ASSESSMENT OF GENE THERAPY (PCCA, MMAB, DOK7 AND COLQ) TO SUPPORT PLATFORM GENE THERAPY FOR CONGENITAL MYASTHENIC DISEASES (DOK7, COLQ) AND ACIDEMIA (PCCA, MMAB) | $1.7M |
| Sep 20, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00004 | 541715 | CHARACTERIZATION OF A DOWNSTREAM GENE THERAPEUTIC FOR THE REPARATIVE TREATMENT OF SEVERE FRACTURES PERIOD OF PERFORMANCE SEPTEMBER 24, 2020 - NOVEMBER 23, 2021 | $133K |
| Sep 17, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00002 | 541715 | CHARACTERIZATION OF A NON-ADDICTIVE SMALL MOLECULE THERAPEUTICS FOR THE MANAGEMENT OF NON-CANCER PAIN PERIOD OF PERFORMANCE SEPTEMBER 18, 2020 - SEPTEMBER 17, 2022 | $121K |
| Aug 27, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92024P00303 | 541380 | 24-015894 NHLBI POPULATION SCIENCES BRANCH REQUIRES PULMONARY FUNCTION TESTING TO DETERMINE IF THE FLEXIVENT METHOD OF PULMONARY FUNCTION TESTING IS SUITABLE TO BE USED IN A LARGER STUDY. | $17K |
| Aug 19, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00005 | 541715 | EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN PROPIONIC ACIDEMIA (PA) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT. PERIOD OF PERFORMANCE SEPTEMBER 25, 2020 - SEPTEMBER 24, 2022 | $48K |
| Aug 14, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123F61001 | 541714 | RADNUC 2201: PERFORMANCE VERIFICATION OF INSTITUTIONAL RADIATION DOSE RESPONSE FOR ACUTE RADIATION SYNDROME (ARS) ANIMAL MODELS (RODENT, RABBIT, MINIPIG, OR NON-HUMAN PRIMATE [NHP]) | $1.7M |
| Aug 6, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95024F00001 | 541714 | KICK-OFF MEETING FOR THE PHARMACOLOGY STUDIES AND ANIMAL MODEL DEVELOPMENT AND RELATED SERVICES FOR DRUG DEVELOPMENT IDIQ CONTRACT. | $1K |
| Aug 1, 2024 | Department of DefenseARMY MED RES ACQ ACTIVITY | W81XWH22P0157 | 511210 | LICENSE AND MAINTENANCE SUPPORT, ON-SITE SUPPORT SERVICES FOR VSP WRAIR. | $225K |
| Jul 18, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123F61001 | 541714 | BIO-AMT-2301: IDIQ CONTRACT MANAGEMENT SUPPORT ACTIVITIES | $37K |
| Jun 17, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95022F00001 | 541715 | BIOANALYTICAL SUPPORTS FOR A GLP TOX/BIODISTRIBUTION STUDY IN MINI-PIGS | $44K |
| Mar 20, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95024F00001 | 541715 | EVALUATION OF POTENTIAL RESPIRATORY STIMULANT. TO4. PERIOD OF PERFORMANCE: MARCH 21, 2024 - MARCH 20, 2025. | $141K |
| Mar 20, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95024F00002 | 541715 | RESPIRATORY INTERACTION STUDIES IN RODENTS, ABILITY OF A TEST ARTICLE TO REVERSE THE RESPIRATORY DEPRESSANT EFFECTS OF OPIOIDS. TO5. PERIOD OF PERFORMANCE: MARCH 21, 2024 - MARCH 20, 2025. | $211K |
| Jan 9, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00005 | 541715 | EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN PROPIONIC ACIDEMIA (PA) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT. PERIOD OF PERFORMANCE SEPTEMBER 25, 2020 - SEPTEMBER 24, 2022 | $3K |
| Dec 19, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92024F00001 | 541714 | GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY - TASK AREA A: CORE ADMINISTRATIVE ACTIVITIES | $11K |
| Nov 15, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95023F00001 | 541715 | CHARACTERIZATION OF SPONTANEOUS OSTEOGENESIS AFTER SURGICAL SEGMENTAL BONE DEFECT IN A LARGE ANIMAL | $192K |
| Sep 29, 2023 | Department of Health and Human ServicesFDA OFFICE OF ACQ GRANT SVCS | 75F40123F19002 | 541690 | TASK ORDER 2 - EXAMINING THE INFLUENCE OF SYNTHETIC COOLING AGENTS ON CIGARETTE SENSORY AND SUBJECTIVE EFFECTS AND USE BEHAVIOR | $1.3M |
| Sep 29, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95023F00002 | 541715 | EFFICACY AND SAFETY EVALUATION OF LEAD GENE THERAPY CANDIDATE IN NEUROMUSCULAR JUNCTION (NMJ) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT | $1.6M |
| Sep 27, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123F61001 | 541714 | RADNUC 2201: PERFORMANCE VERIFICATION OF INSTITUTIONAL RADIATION DOSE RESPONSE FOR ACUTE RADIATION SYNDROME (ARS) ANIMAL MODELS (RODENT, RABBIT, MINIPIG, OR NON-HUMAN PRIMATE [NHP]) | $2.0M |
| Sep 27, 2023 | Department of Health and Human ServicesFDA OFFICE OF ACQ GRANT SVCS | 75F40123F19001 | 541690 | TASK ORDER 1 -TITLE: ARE REDUCTIONS IN BOE, BOPH, AND OTHER HEALTH RISK MARKERS PROPORTIONAL TO REDUCTIONS IN CIGARETTE SMOKING UPON SWITCHING TO ENDS | $3.9M |
| Sep 27, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00005 | 541715 | EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN PROPIONIC ACIDEMIA (PA) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT. PERIOD OF PERFORMANCE SEPTEMBER 25, 2020 - SEPTEMBER 24, 2022 | $380K |
| Sep 26, 2023 | Department of Health and Human ServicesFDA OFFICE OF ACQ GRANT SVCS | 75F40123D00039 | 541690 | AWARD OF FIVE-YEAR IDIQ FOR CTP- ASSESSING TOBACCO-RELATED CLINICAL OUTCOMES AND HUMAN BEHAVIORS IN TOBACCO | $5K |
| Sep 22, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92023F00001 | 541714 | GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY | $234K |
| Sep 19, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00003 | 541715 | NATURAL HISTORY STUDIES IN NEUROMUSCULAR JUNCTION (NMJ) DISEASE MOUSE MODELS. PERIOD OF PERFORMANCE SEPTEMBER 28, 2020 - DECEMBER 31, 2021 | $17K |
| Sep 11, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 75N92023P00366 | 541380 | EVALUATION OF AN ASO IN THE MOUSE CIGARETTE SMOKE AND INFLUENZA MODEL | $171K |
| Aug 29, 2023 | Department of Health and Human ServicesFDA OFFICE OF ACQ GRANT SVCS | 75F40122F19001 | 541690 | CTP-2022-111127 - SALTS | $53K |
| Aug 28, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95021F00001 | 541715 | CHARACTERIZATION OF A NON-PARALYZING BONT-BASED BIOPHARMACEUTICAL FOR THE TREATMENT OF NEUROPATHIC PAIN | $128K |
| Aug 25, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00002 | 541715 | CHARACTERIZATION OF A NON-ADDICTIVE SMALL MOLECULE THERAPEUTICS FOR THE MANAGEMENT OF NON-CANCER PAIN PERIOD OF PERFORMANCE SEPTEMBER 18, 2020 - SEPTEMBER 17, 2022 | $169K |
| Aug 25, 2023 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | W81XWH22P0157 | 511210 | LICENSE AND MAINTENANCE SUPPORT, ON-SITE SUPPORT SERVICES FOR VSP WRAIR. | $219K |
| Aug 3, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95023F00001 | 541715 | CHARACTERIZATION OF SPONTANEOUS OSTEOGENESIS AFTER SURGICAL SEGMENTAL BONE DEFECT IN A LARGE ANIMAL | $194K |
| Aug 2, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123F61001 | 541714 | BIO-AMT-2301: IDIQ CONTRACT MANAGEMENT SUPPORT ACTIVITIES | $20K |
| Jun 28, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93023F00001 | 541715 | GUARANTEED MINIMUM | $18K |
| Apr 5, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93023F00001 | 541715 | GUARANTEED MINIMUM | $3K |
Get Alerted Before Lovelace Biomedical Research Institute's Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start for free